Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum
Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that Dr. Thomas A. Ciulla will present a company overview at the Ophthalmology Futures European 2021 Virtual Retina Forum on September 8, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that Dr. Thomas A. Ciulla will present a company overview at the Ophthalmology Futures European 2021 Virtual Retina Forum on September 8, 2021. The event focuses on advancements in treating back of the eye diseases. The company specializes in biopharmaceuticals aimed at restoring vision, utilizing its proprietary SCS Microinjector® for targeted medication delivery. Archived webcasts will be available for three months on the Clearside website.
Details
News Market Reaction – CLSD
The recorded move for CLSD in the trading session of this news was +11.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, Ga., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a company overview at the Ophthalmology Futures European 2021 Virtual Retina Forum on September 8, 2021. Access to the event is available here.
A link to the archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.